Lucentis works very well in AMD, so does its sister drug Avastin at a significantly cheaper price. As Will points out, Regeneron is seeking FDA approval of Eylea for AMD, with a decision expected in November.
Frankly, squalamine doesn't stand a chance. Genaera was developing an intravenous version of the drug, which Ohr has somehow reformulated into an eye drop. How and why the eye drop version will work better than the IV formulation isn't clear. Surely, treating AMD with an eye drop is more patient friendly than the eye injection required for drugs like Lucentis, Avastin or Eylea. But investors should be under no illusion that squalamine -- a tired, old and failed drug -- has any real shot at resurrection.
That's why Ohr was able to buy the drug for just $200,000 in the first place.
--Written by Adam Feuerstein in Boston
>To contact the writer of this article, click here: Adam Feuerstein.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV